drugset / Trial / NCT01053897

Study of GBT009 for Treatment of Incisional Wounds Following Breast Reconstruction Surgery

NCT01053897 ↗

Phase 2 Completed 5 enrolled Garnet BioTherapeutics, Inc.
RandomizedSingle-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to assess whether intradermal injections of GBT009 along full thickness incisions following surgery results in an improvement in scar appearance.

Timeline

Start
2010-01
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject GBT009 Unknown — Other

Indications

No indication recorded.